Literature DB >> 17385664

Hypercomplementemia in adult patients with IgA nephropathy.

Kisara Onda1, Hiroyuki Ohi, Mariko Tamano, Isao Ohsawa, Michiro Wakabayashi, Satoshi Horikoshi, Teizo Fujita, Yasuhiko Tomino.   

Abstract

IgA nephropathy (IgAN) is the most common form of chronic glomerulonephritis. Although glomerular deposition of complement components is well known, the evidence of serological complement activation in IgAN is inconclusive. We hypothesized that serum levels of complement components and regulatory proteins in patients with IgAN are correlated with its pathogenesis. In the present study we measured complement components in 50 patients with IgAN and 50 healthy volunteers. C5, C1 inhibitor, factor B, C4 binding protein, factor H, and factor I were measured with the use of single radial immunodiffusion. Mannose-binding lectin (MBL) and properdin (P) were measured by enzyme-linked immunosorbent assay (ELISA). The correlations among complements in the sera of patients with clinical gradings for IgAN (i.e., the good prognosis group, relatively good prognosis group, relatively poor prognosis group, and poor prognosis group) were evaluated. CH50, C4, factor B, P, factor I, and factor H were significantly higher in IgAN patients than in healthy controls. There were significant correlations between C5 and C4 binding protein, between C3 and C5, or between C4 and factor B in patients with IgAN. In the poor prognosis group, C4 binding protein was significantly higher than in the other groups of IgAN patients. hypercomplementemia occurs in IgAN and is associated with an increase in complement regulatory protein (CRP). C4 binding protein analyses can be used to predict disease prognosis. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17385664      PMCID: PMC6649110          DOI: 10.1002/jcla.20154

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  36 in total

1.  Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies.

Authors:  M Tomana; J Novak; B A Julian; K Matousovic; K Konecny; J Mestecky
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

2.  Increased thrombin generation in patients with chronic renal failure.

Authors:  A Sagripanti; V Cozza; U Baicchi; M Camici; A Cupisti; G Barsotti
Journal:  Int J Clin Lab Res       Date:  1997

3.  IgA nephropathy: clinicopathology and immunopathology.

Authors:  T Shirai; Y Tomino; M Sato; T Yoshiki; T Itoh
Journal:  Contrib Nephrol       Date:  1978       Impact factor: 1.580

4.  The activation of the C3b feedback cycle with human complement components. I. Through the classical pathway.

Authors:  L W Mak; P J Lachmann; J Majewski
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

5.  Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy.

Authors:  M Matsuda; K Shikata; J Wada; H Sugimoto; Y Shikata; T Kawasaki; H Makino
Journal:  Nephron       Date:  1998-12       Impact factor: 2.847

6.  Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins.

Authors:  T Kokubo; Y Hiki; H Iwase; A Tanaka; K Toma; K Hotta; Y Kobayashi
Journal:  J Am Soc Nephrol       Date:  1998-11       Impact factor: 10.121

7.  Serum levels and in vitro production of IgA subclasses in patients with primary IgA nephropathy.

Authors:  A W van den Wall Bake; M R Daha; A van der Ark; P S Hiemstra; J Radl; L A van Es
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

8.  Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry.

Authors:  P A Johnston; J S Brown; D A Braumholtz; A M Davison
Journal:  Q J Med       Date:  1992-08

9.  Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.

Authors:  A C Allen; S J Harper; J Feehally
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

10.  Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version.

Authors:  Yasuhiko Tomino; Hideto Sakai
Journal:  Clin Exp Nephrol       Date:  2003-06       Impact factor: 2.801

View more
  16 in total

1.  Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.

Authors:  Min Pan; QiongXiu Zhou; ShuBei Zheng; XiaoHan You; Duo Li; Ji Zhang; ChaoSheng Chen; FeiFei Xu; ZhanYuan Li; ZhiHong Zhou; JianNa Zhang
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression.

Authors:  B Faria; C Henriques; A C Matos; M R Daha; M Pestana; M Seelen
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 3.  Pathogenetic and therapeutic approaches to IgA nephropathy using a spontaneous animal model, the ddY mouse.

Authors:  Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2010-11-06       Impact factor: 2.801

4.  Comparative proteomic analysis of renal tissue in IgA nephropathy with iTRAQ quantitative proteomics.

Authors:  Weiguo Sui; Zhenzhen Cui; Ruohan Zhang; Wen Xue; Minglin Ou; Guimian Zou; Jiejing Chen; Yong Dai
Journal:  Biomed Rep       Date:  2014-07-23

Review 5.  Current Understanding of the Role of Complement in IgA Nephropathy.

Authors:  Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2015-02-18       Impact factor: 10.121

6.  Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy.

Authors:  Feng Ping Ji; Lu Wen; Yan Ping Zhang; Er Peng Liu; Jian Guo Wen
Journal:  Int Urol Nephrol       Date:  2021-09-28       Impact factor: 2.370

7.  Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.

Authors:  Li Zhu; Ya-Ling Zhai; Feng-Mei Wang; Ping Hou; Ji-Cheng Lv; Da-Min Xu; Su-Fang Shi; Li-Jun Liu; Feng Yu; Ming-Hui Zhao; Jan Novak; Ali G Gharavi; Hong Zhang
Journal:  J Am Soc Nephrol       Date:  2014-09-09       Impact factor: 10.121

8.  Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.

Authors:  Kisara Onda; Isao Ohsawa; Hiroyuki Ohi; Mariko Tamano; Satoshi Mano; Michiro Wakabayashi; Akie Toki; Satoshi Horikoshi; Teizo Fujita; Yasuhiko Tomino
Journal:  BMC Nephrol       Date:  2011-11-23       Impact factor: 2.388

9.  Implication of urinary complement factor H in the progression of immunoglobulin A nephropathy.

Authors:  Maojing Liu; Yuqing Chen; Jingjing Zhou; Ying Liu; Fengmei Wang; Sufang Shi; Yanfeng Zhao; Suxia Wang; Lijun Liu; Jicheng Lv; Hong Zhang; Minghui Zhao
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

Review 10.  Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy.

Authors:  Isao Ohsawa; Masaya Ishii; Hiroyuki Ohi; Yasuhiko Tomino
Journal:  J Biomed Biotechnol       Date:  2012-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.